Literature DB >> 9724556

Aggregation of recombinant human interferon gamma: kinetics and structural transitions.

B S Kendrick1, J L Cleland, X Lam, T Nguyen, T W Randolph, M C Manning, J F Carpenter.   

Abstract

Protein aggregation is a complex phenomenon that can occur in vitro and in vivo, usually resulting in the loss of the protein's biological activity. While many aggregation studies focus on a mechanism due to a specific stress, this study focuses on the general nature of aggregation. Recombinant human interferon-gamma (rhIFN-gamma) provides an ideal model for studying protein aggregation, as it has a tendency to aggregate under mild denaturing stresses (low denaturant concentration, temperature below the Tm, and below pH 5). All of the aggregates induced by these stresses have a similar structure (high in intermolecular beta-sheet content and a large loss of alpha-helix) as determined by infrared and circular dichroism spectroscopy. Thermally induced and denaturant-induced aggregation processes follow first-order kinetics under the conditions of this study. Spectroscopic and kinetic data suggest that rhIFN-gamma aggregates through an intermediate form possessing a large amount of residual secondary structure. In contrast to the aggregates formed under denaturing stresses, the salted-out protein has a remarkably nativelike secondary structure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724556     DOI: 10.1021/js9801384

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  29 in total

1.  Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy.

Authors:  M Bouchard; J Zurdo; E J Nettleton; C M Dobson; C V Robinson
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

2.  A general approach to renaturation of recombinant proteins produced as inclusion bodies.

Authors:  A N Wulfson; R V Tikhonov; S E Pechenov
Journal:  Dokl Biochem Biophys       Date:  2001 Sep-Oct       Impact factor: 0.788

3.  Pressure- and temperature-induced unfolding and aggregation of recombinant human interferon-gamma: a Fourier transform infrared spectroscopy study.

Authors:  Koen Goossens; Joost Haelewyn; Filip Meersman; Marc De Ley; Karel Heremans
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

Review 4.  Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Theodore W Randolph; John F Carpenter
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

5.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

6.  FTIR and nDSC as analytical tools for high-concentration protein formulations.

Authors:  Susanne Matheus; Wolfgang Friess; Hanns-Christian Mahler
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

Review 7.  Through the looking glass: the protein science of biosimilars.

Authors:  David Goldsmith; Martin Kuhlmann; Adrian Covic
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

8.  A multi-tiered analytical approach for the analysis and quantitation of high-molecular-weight aggregates in a recombinant therapeutic glycoprotein.

Authors:  Heather Hughes; Charles Morgan; Elizabeth Brunyak; Kristen Barranco; Emily Cohen; Tim Edmunds; Karen Lee
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

9.  Antibody protein array analysis of the tear film cytokines.

Authors:  Shimin Li; Robert Sack; Trinka Vijmasi; Sonal Sathe; Ann Beaton; David Quigley; Marianne Gallup; Nancy A McNamara
Journal:  Optom Vis Sci       Date:  2008-08       Impact factor: 1.973

10.  A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma.

Authors:  B S Kendrick; J F Carpenter; J L Cleland; T W Randolph
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.